Circulating soluble Fas levels in patients with hepatitis C virus infection and interferon therapy

The clinical relevance of the circulating soluble form of the Fas-Receptor (sFas) was investigated in patients with hepatitis C receiving type 1 interferon (IFN) therapy. sFas was quantified by enzyme-linked immunosorbent assay in 66 hepatitis C virus (HCV) carriers and 30 HCV-naive or previously in...

Full description

Saved in:
Bibliographic Details
Published in:Journal of gastroenterology 2004-12, Vol.39 (12), p.1189-1195
Main Authors: Kakiuchi, Yoshimi, Yuki, Nobukazu, Iyoda, Kenya, Sugiyasu, Yasunori, Kaneko, Akira, Kato, Michio
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
fas Receptor - blood
Female
Hepatitis C - blood
Hepatitis C - drug therapy
Humans
Interferon-alpha - therapeutic use
Interferon-beta - therapeutic use
Male
Middle Aged
Recombinant Proteins
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The clinical relevance of the circulating soluble form of the Fas-Receptor (sFas) was investigated in patients with hepatitis C receiving type 1 interferon (IFN) therapy. sFas was quantified by enzyme-linked immunosorbent assay in 66 hepatitis C virus (HCV) carriers and 30 HCV-naive or previously infected controls. The levels were then monitored during enhanced treatment with type 1 IFNs in 15 chronic hepatitis C patients. The HCV carriers had high levels of sFas compared with controls (3.8+/-1.3 vs 2.7+/-0.8 ng/ml; P
ISSN:0944-1174
1435-5922
DOI:10.1007/s00535-004-1470-2